ALCLOMETASONE
Sponsors
Anaptysbio Inc.
Conditions
Atopic Dermatitis
Phase 2
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis
WithdrawnCTIS2023-503522-40-00
Target: 60Updated: 2023-09-18
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis
CompletedCTIS2023-503522-40-01
Start: 2024-04-10End: 2024-12-11Target: 84Updated: 2024-10-22